Access signs pre-licensing feasibility agreement Print E-mail
By Staff and Wire Reports   
Wednesday, 27 October 2010 00:00

In early October, we told our readers that Access Pharmaceuticals' (OTC: ACCP) stock had been acting very bullishly. Today's news looks to add fuel to their climb.

The upward trend has, indeed, continued higher for ACCP and this morning, the Company announced that it has entered into a pre-licensing feasibility agreement with a leading biopharmaceutical company to develop an oral formulation of an undisclosed prostate cancer compound utilizing its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology. 

Just last week, ACCP submitted additional patent applications, covering that oral drug delivery technology formulations for many of the world's top-100 injectable drugs- all as a result of the growing interest surrounding the company’s proprietary oral delivery technology. 

“This is another important step for Access as we now have several ongoing collaborations, pre-licensing agreements and continued interest from additional top-tier partners for our CobOral Drug Delivery Technology,” said Phillip Wise, Vice President for Business Development and Strategy, Access Pharmaceuticals, Inc.  He continued, “Having recently rebranded our Vitamin-B12 oral-delivery technology to CobOral has helped raise our visibility with pharmaceutical and biotechnology companies in search for a novel broad-based oral drug-delivery technology and we anticipate moving forward on various applications of our CobOral platform.”

Jeffrey B. Davis, President and CEO, Access Pharmaceuticals had hinted that “the CobOral branding and additional patent filings reflect the high level of interest from partners in our CobOral and CobaCyte drug delivery platforms.”

According to a press-release issued by the company, Access will develop CobOral formulations for testing by the undisclosed biopharma company. Access indicated that any successful formulation developed will be jointly owned by the Parties and subject to a subsequent full licensing agreement.

Developing...




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter